MBX BIOSCIENCES INC (MBX) Fundamental Analysis & Valuation

NASDAQ:MBX • US55287L1017

Current stock price

32.96 USD
+0.15 (+0.46%)
At close:
32.96 USD
0 (0%)
After Hours:

This MBX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. MBX Profitability Analysis

1.1 Basic Checks

  • MBX had negative earnings in the past year.
  • MBX had a negative operating cash flow in the past year.
MBX Yearly Net Income VS EBIT VS OCF VS FCFMBX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 2025 -20M -40M -60M -80M

1.2 Ratios

  • MBX's Return On Assets of -22.58% is in line compared to the rest of the industry. MBX outperforms 58.64% of its industry peers.
  • With a decent Return On Equity value of -23.56%, MBX is doing good in the industry, outperforming 66.49% of the companies in the same industry.
Industry RankSector Rank
ROA -22.58%
ROE -23.56%
ROIC N/A
ROA(3y)-28.11%
ROA(5y)N/A
ROE(3y)-29.46%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MBX Yearly ROA, ROE, ROICMBX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 2025 -20 -40 -60

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for MBX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MBX Yearly Profit, Operating, Gross MarginsMBX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. MBX Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for MBX has been increased compared to 1 year ago.
  • MBX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MBX Yearly Shares OutstandingMBX Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 2025 10M 20M 30M 40M
MBX Yearly Total Debt VS Total AssetsMBX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 2025 100M 200M 300M

2.2 Solvency

  • MBX has an Altman-Z score of 58.23. This indicates that MBX is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 58.23, MBX belongs to the top of the industry, outperforming 95.29% of the companies in the same industry.
  • MBX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 58.23
ROIC/WACCN/A
WACCN/A
MBX Yearly LT Debt VS Equity VS FCFMBX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 2025 0 100M 200M 300M

2.3 Liquidity

  • MBX has a Current Ratio of 24.62. This indicates that MBX is financially healthy and has no problem in meeting its short term obligations.
  • MBX has a better Current ratio (24.62) than 95.29% of its industry peers.
  • A Quick Ratio of 24.62 indicates that MBX has no problem at all paying its short term obligations.
  • The Quick ratio of MBX (24.62) is better than 95.29% of its industry peers.
Industry RankSector Rank
Current Ratio 24.62
Quick Ratio 24.62
MBX Yearly Current Assets VS Current LiabilitesMBX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. MBX Growth Analysis

3.1 Past

  • MBX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.57%, which is quite good.
EPS 1Y (TTM)16.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.26%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • MBX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.50% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-22.66%
EPS Next 2Y-30.81%
EPS Next 3Y-21.81%
EPS Next 5Y11.5%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MBX Yearly Revenue VS EstimatesMBX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 2033 500M 1B
MBX Yearly EPS VS EstimatesMBX Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5 10 -10

More info and screens

Find the best growth stocksShow best growing peers

0

4. MBX Valuation Analysis

4.1 Price/Earnings Ratio

  • MBX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MBX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MBX Price Earnings VS Forward Price EarningsMBX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MBX Per share dataMBX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

  • A cheap valuation may be justified as MBX's earnings are expected to decrease with -21.81% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-30.81%
EPS Next 3Y-21.81%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MBX Dividend Analysis

5.1 Amount

  • MBX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MBX Fundamentals: All Metrics, Ratios and Statistics

MBX BIOSCIENCES INC

NASDAQ:MBX (4/15/2026, 8:03:49 PM)

After market: 32.96 0 (0%)

32.96

+0.15 (+0.46%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-12
Earnings (Next)05-11
Inst Owners80.72%
Inst Owner Change-0.12%
Ins Owners2.89%
Ins Owner Change2.55%
Market Cap1.57B
Revenue(TTM)N/A
Net Income(TTM)-86.97M
Analysts82.67
Price Target62.53 (89.71%)
Short Float %10.01%
Short Ratio6.14
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.24%
Min EPS beat(2)10.09%
Max EPS beat(2)20.39%
EPS beat(4)4
Avg EPS beat(4)15.9%
Min EPS beat(4)8.71%
Max EPS beat(4)24.42%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.33%
PT rev (3m)3.46%
EPS NQ rev (1m)13.83%
EPS NQ rev (3m)18.67%
EPS NY rev (1m)2.06%
EPS NY rev (3m)8.11%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.24
P/tB 4.24
EV/EBITDA N/A
EPS(TTM)-2.41
EYN/A
EPS(NY)-2.96
Fwd EYN/A
FCF(TTM)-1.72
FCFYN/A
OCF(TTM)-1.68
OCFYN/A
SpS0
BVpS7.77
TBVpS7.77
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -22.58%
ROE -23.56%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-28.11%
ROA(5y)N/A
ROE(3y)-29.46%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 777.82%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 24.62
Quick Ratio 24.62
Altman-Z 58.23
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)406.06%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.26%
EPS Next Y-22.66%
EPS Next 2Y-30.81%
EPS Next 3Y-21.81%
EPS Next 5Y11.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-43.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-43.01%
EBIT Next 3Y-42.43%
EBIT Next 5Y-2.74%
FCF growth 1Y-47.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-46.21%
OCF growth 3YN/A
OCF growth 5YN/A

MBX BIOSCIENCES INC / MBX Fundamental Analysis FAQ

What is the ChartMill fundamental rating of MBX BIOSCIENCES INC (MBX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to MBX.


What is the valuation status of MBX BIOSCIENCES INC (MBX) stock?

ChartMill assigns a valuation rating of 0 / 10 to MBX BIOSCIENCES INC (MBX). This can be considered as Overvalued.


How profitable is MBX BIOSCIENCES INC (MBX) stock?

MBX BIOSCIENCES INC (MBX) has a profitability rating of 1 / 10.


Can you provide the financial health for MBX stock?

The financial health rating of MBX BIOSCIENCES INC (MBX) is 8 / 10.